Fig. 1: Immunogenicity of PfCyRPA virosomes in mice. | npj Vaccines

Fig. 1: Immunogenicity of PfCyRPA virosomes in mice.

From: Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

Fig. 1

Development of anti-PfCyRPA total IgG responses in BALB/c (a) and NMRI (b) mice after each immunisation. Sera were taken pre-immune (pre imm), after pre-immunisation with inactivated influenza virus (post flu priming) and after the first (1. imm), second (2. imm) and third (3. imm) immunisation with PfCyRPA virosomes. Shown are serum IgG ELISA endpoint titers of individual animals and lines represent the mean. Two independent experiments yielded comparable results; representative data of a single assay is shown. Determination of the IgG subclass profiles in BALB/c (c) and NMRI (d) mice by ELISA using plates coated with recombinant PfCyRPA. Sera from mice collected after the third immunisation were tested individually at three serum dilutions. Optical density (OD) values form a single experiment are shown; these are representative for the two independent assays. Avidity index for the anti-PfCyRPA IgG responses of BALB/c (e) and NMRI (f) mice three weeks after the first, second and third immunisation. The avidity index is the NH4SCN concentration (M) where 50% of the bound antibodies are eluted. Shown are results from a single experiment obtained with individual sera tested in triplicates and the median (line) for each time point.

Back to article page